港交所(00388.HK)冀成全球最大生物科技企业集资中心
港交所(00388.HK)主席史美伦於网上研讨会辞词时表示,本港修改上市规则,容许未有盈利的生物科技股份上市不久,已成为亚洲第一及全球第二大生物科技企业集资中心。行政总裁李小加表示,相关表现仍然不够,希望未来五至十年,本港可成全最大生物科技企业集资中心。
李小加指,本港具备相关条件,主要由於中国内地面对14亿人口的健康及人口老化问题,须发展医疗及生化科技。而若要市场健康发展,他指须提升政府及监管对有关方面的透明度。
另外史美伦亦透露,首七个月本港新股集资金额已按年增加56%,未来六个月亦有多间公司上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.